% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gear:275587,
      author       = {J. Gear and C. Stokke and C. Terwinghe and S. Gnesin and M.
                      Sandström and J. Tran-Gia and M. Cremonesi and F. Cicone
                      and F. Verburg and R. Hustinx and L. Giovanella and K.
                      Herrmann$^*$ and P. M. Gabiña},
      title        = {{EANM} enabling guide: how to improve the accessibility of
                      clinical dosimetry.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {50},
      number       = {7},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DKFZ-2023-00798},
      pages        = {1861-1868},
      year         = {2023},
      note         = {2023 Jun;50(7):1861-1868},
      abstract     = {Dosimetry can be a useful tool for personalization of
                      molecular radiotherapy (MRT) procedures, enabling the
                      continuous development of theranostic concepts. However, the
                      additional resource requirements are often seen as a barrier
                      to implementation. This guide discusses the requirements for
                      dosimetry and demonstrates how a dosimetry regimen can be
                      tailored to the available facilities of a centre. The aim is
                      to help centres wishing to initiate a dosimetry service but
                      may not have the experience or resources of some of the more
                      established therapy and dosimetry centres. The
                      multidisciplinary approach and different personnel
                      requirements are discussed and key equipment reviewed
                      example protocols demonstrating these factors are given in
                      the supplementary material for the main therapies carried
                      out in nuclear medicine, including [131I]-NaI for benign
                      thyroid disorders, [177Lu]-DOTATATE and 131I-mIBG for
                      neuroendocrine tumours and [90Y]-microspheres for
                      unresectable hepatic carcinoma.},
      keywords     = {Dosimetry (Other) / Molecular radiotherapy (Other) /
                      Nuclear medicine (Other) / Optimisation (Other) /
                      Quantitative imaging (Other) / SPECT (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37086275},
      doi          = {10.1007/s00259-023-06226-z},
      url          = {https://inrepo02.dkfz.de/record/275587},
}